What is HC Wainwright’s Forecast for ARQT Q1 Earnings?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Arcutis Biotherapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.20 EPS, FY2027 earnings at $1.18 EPS, FY2028 earnings at $1.89 EPS and FY2029 earnings at $2.43 EPS.

Other equities analysts have also recently issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and issued a $20.00 target price on shares of Arcutis Biotherapeutics in a report on Wednesday, April 9th. Guggenheim reissued a “buy” rating on shares of Arcutis Biotherapeutics in a report on Thursday, April 3rd. The Goldman Sachs Group upped their target price on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Thursday, February 27th. Jefferies Financial Group lifted their price objective on shares of Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, March 11th. Finally, Mizuho increased their target price on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.80.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $13.57 on Thursday. Arcutis Biotherapeutics has a one year low of $6.99 and a one year high of $17.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -7.58 and a beta of 1.87. The company’s 50-day simple moving average is $14.77 and its 200-day simple moving average is $13.17.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Tuesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. The business had revenue of $65.85 million for the quarter, compared to analyst estimates of $64.80 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%.

Insider Activity

In related news, Director Howard G. Welgus sold 10,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $13.00, for a total transaction of $130,000.00. Following the transaction, the director now directly owns 131,944 shares in the company, valued at $1,715,272. The trade was a 7.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Masaru Matsuda sold 5,030 shares of the firm’s stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $15.20, for a total transaction of $76,456.00. Following the transaction, the insider now owns 204,399 shares of the company’s stock, valued at approximately $3,106,864.80. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,791 shares of company stock valued at $474,719. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Arcutis Biotherapeutics by 45.8% in the third quarter. Barclays PLC now owns 253,392 shares of the company’s stock valued at $2,356,000 after purchasing an additional 79,579 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Arcutis Biotherapeutics by 0.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,296,911 shares of the company’s stock valued at $12,061,000 after purchasing an additional 11,833 shares during the last quarter. LVW Advisors LLC bought a new position in Arcutis Biotherapeutics during the fourth quarter worth about $166,000. SG Americas Securities LLC lifted its position in shares of Arcutis Biotherapeutics by 25.4% in the fourth quarter. SG Americas Securities LLC now owns 48,087 shares of the company’s stock valued at $670,000 after buying an additional 9,754 shares during the last quarter. Finally, Zweig DiMenna Associates LLC bought a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $578,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.